Pharma / Biotech
Part 1: Quantitation Assays
Quantitation assays are critical for the development of biologics and biopharmaceuticals as well as accurate detection of protein biomarkers. Immunoassays for quantitation of protein drugs in biological matrices (ex. plasma, serum, tissue) generally take much longer to develop and are subject to a wider range of interferences than traditional xenobiotic small molecule quantitation assays by LC-MS/MS. Part 1 of this interactive two day course focuses on these critical assays and will take you step-by-step through the development of quantitation assays for proteins including monoclonal antibodies.
The course begins with basic development, highlighting technical requirements, regulatory requirements and industry trends. We start by detailing how to select and maintain critical reagents, then move to assay formats. This includes understanding physical processes behind the four parameter model and how to interpret curve shape in terms of assay optimization. Then we move into qualification and validation of the assays to support pre-clinical and clinical studies. Part 1 of this course ends with preparation of the assay for use in a bioanalytical laboratory, including validation, establishing robustness, determining acceptable and practical system suitability criteria and suggestions for long term maintenance of the assay.
Part 2: Immunogenicity Assays
Part 2 of this course starts with an overview of immunology followed by the requirements of an immunogenicity program, including the establishment of a tiered testing approach for screening, confirmation assay analysis, titer assays and neutralizing antibody assays. The course then goes on to cover basic development of these assays, highlighting how to develop and label critical antibody reagents, different assay formats (ex. bridge, sandwich), including an analysis of strengths and weaknesses of each format. This is followed by a review of current scientific guidelines on how to establish cut-points (with a hands on calculation workshop with sample data at the end of the course). Optimization of screening assays to improve sensitivity and minimize outliers is also reviewed. The sensitivity of various assays to drug (assay drug tolerance) will be discussed and an overview of available technologies and sample pre-treatment approaches will be reviewed. Then we move into validation of the assays to support pre-clinical and clinical studies. The course will end with concepts of risk based testing approaches.
This course has been pre-approved by the Regulatory Affairs Professionals Society (RAPS) as eligible for 12 credits towards a participant's RAC recertification upon full completion.
This two-day, two-part course is designed for those who perform, supervise, manage, audit, or oversee the validation of bioanalytical assays in a GLP laboratory. This includes, but is not limited to, professionals in Analytical Development, Quality Control, Quality Assurance, Validation, Regulatory Affairs, Pharmaceutical Development, Clinical Development, Medical Development, and Research and Development groups.
This course will also be of interest to Biopharmaceutical Development Companies, Biosimilar Drug Development Professionals, Regulatory Assessors, Consultants, and Clinical Laboratories.
Session 1: Immunochemistry Basics
Session 2: Assay Formats
Session 3: Modeling and Analyzing Data
Session 4: Assay Validation
Session 5: Practical Development and Validation Workshop
Session 6: Immunology
Session 7: Testing Considerations
Session 8:Bioanalytical Testing
Session 9:Assay Design
Session 10: Regulatory Guidelines for Validation
Session 11: Risk Based Approach to Testing
Session 12: Assay Validation and Cut-Point Determination Workshop
Upon completion of this course, attendees will have a clear understanding of regulatory agency expectations for bioanalytical development, and will have gained the background knowledge necessary to effectively plan bioanalytical assay development and validation programs for both quantitation assays and PK studies. Additionally, participants will learn to develop immunogenicity assays for detecting anti-drug antibodies for both marketed products and products in clinical development. Attendees will develop expertise in writing protocols, reports performing calculations, and acceptance limits for bioassay method validation.
Participants will have acquired insight into how to avoid common development and validation pitfalls and be able to quickly discriminate compliant from non-compliant validation activities. In addition, attendees will gain practical experience in applying what they have learned during hands on problem solving and calculations workshops.
"This course was very comprehensive, practical and clear; given by a Course Director 'who has been there.'" Denis Groleau, Group Leader & Sr. Research Officer, BRI-NRC
Each person attending a course will be asked to set up an Attendee Profile Account during the registration process.
Accounts are a new feature on our website. Creating an Account helps you view your order history and manage your training programs.
If you are registering for others, please set up an Account in the Attendee’s name. If you are
registering more than one person, you’ll need to set up a separate account for each Attendee.
*Valid up to 30 days prior to course date(s). Cannot be combined with other discounts or offers.
The Center for Professional Innovation and Education (CfPIE) provides technical training for Pharmaceutical, Biotech, Medical Device and Skin/Cosmetics professionals. CfPIE offers more than 350 class sessions annually across 80 course titles in multiple formats, such as classroom, on-site and certification programs.
Learn more »
Keep up to date with the latest news from CfPIE, including upcoming courses and events.
Members of participating industry organizations receive special discounts for all our training courses.
© 2001 - 2015 CfPIE, Inc. All Rights Reserved.